At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 167 enrolled
Drug / intervention
Necitumumab +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Multicenter, Open-Label, Phase 2 Study of Paclitaxel-Carboplatin Chemotherapy Plus Necitumumab (IMC-11F8) Versus Paclitaxel-Carboplatin Chemotherapy Alone in the First-Line Treatment of Patients With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC)
In Brief
A Phase 2 clinical trial evaluating Necitumumab, Paclitaxel, and 1 other intervention for Squamous Non Small Cell Lung Cancer. Completed, enrolled 167 participants across 51 sites in 6 countries.
Detailed Summary
The main purpose of this study is to evaluate if necitumumab added to standard chemotherapy of paclitaxel and carboplatin is more effective to treat cancer than the standard chemotherapy of paclitaxel and carboplatin alone.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSquamous Non Small Cell Lung Cancer
CountriesGermany, Mexico, Poland, Russia, South Korea, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartJan 2013
First PostedJan 2013
Primary CompletionApr 2015
Study CompletionJul 2017
TodayJul 2026
First PostedJan 16, 2013
Enrollment StartJan 1, 2013
Primary CompletionApr 1, 2015
Study CompletionJul 1, 2017
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 13.5 years ago
Interventions
Necitumumabdrug
Administered IV
Paclitaxeldrug
Administered IV
Carboplatindrug
Administered IV